

Financial Results for the Second Quarter of the Year ending March 31, 2019

- Forward-looking statements for earnings and other performance data contained herein are based on information currently available to the Company, and all potential risks and uncertainties are taken into account. The Company asks that investors understand that changes in conditions may cause actual performance to significantly differ from these projections.
- Amounts in this statement are rounded down to the nearest hundred million.



1. Financial results for the second quarter of the Year ending March 31, 2019

2. Forecast for the Year ending March 31, 2019

3. Capital allocation of post-restructuring

Summary for the First Half of the Year ending March 31, 2019



YoY Result

- Operating Profit was ¥30.6 billion, up ¥7.6 billion.
 - Imaging Products Business decreased its profit because of the initial cost for new products such as full-frame ML cameras and lenses launched in September.
 - Precision Equipment Business profit hike was driven by FPD lithography systems for large-sized panels.
 - Industrial Metrology Business discontinued some of the non-contact 3D metrology systems with low profitability, following the withdrawal from the CMM business last year.
- Restructuring improved profitability, lifting gross margin to the highest in 10 years.

Actual vs. Forecast

- Operating profit surpassed by ¥3.6 billion.
 - Improved profitability of Healthcare Business, etc. and expenditure efficiency improvement by corporate (undistributed) exceeded the profit drop of Imaging Products Business.

 (Profit non-attributable to business segments improved ¥2.2 billion.)

Interim Dividend

- ¥30, up ¥16 from the previous year (¥14).
 - Up ¥3 from the previous forecast

Note: CMM (Coordinate Measuring Machines) business conducts development, manufacture, sales and service activities of contact-type 3D metrology systems.

The previous forecast is as of August 7, 2018.

First Half of the Year ending March 31, 2019: Financial Highlights



Billions of yen	FY2018/3 1H (A)	Previous forecast (B) (Aug. 7)	FY2019/3 1H (C)	Change (C)-(A)	Change (C)-(B)
Revenue	328.4	332.0	335.7	+7.3	+3.7
Operating Profit	23.0	27.0	30.6	+7.6	+3.6
% vs Revenue	7.0%	8.1%	9.1%	, ,	. 5.15
Profit before income taxes	21.4	28.0	33.8	+12.4	+5.8
% vs Revenue	6.5%	8.4%	10.1%		
Profit attributable to owners of the parent	13.9	19.0	22.8	+8.9	+3.8
% vs Revenue	4.2%	5.7%	6.8%		
FCF	7.0	_	31.2	+24.2	_
Exchange Rate:				Impact or	Revenue
US\$	¥111	¥107	¥110	+0.3	+2.5
EURO	¥126	¥130	¥130	Impact on Op	erating Profit
				-1.0	+0.1

1H Profit posted ¥22.8 billion, 64% up from previous year.

First Half of the Year ending March 31, 2019: Financial Highlights by Segments



Billions of yen		FY2018/3 1H (A)	FY2019/3 1H (B)	Change (B)-(A)
Imaging	Revenue	175.2	150.9	-14%
Products	Operating	15.4	13.2	-2.2
Business	Profit	(15.4)	(13.6)	
Precision	Revenue	98.0	121.6	+24%
Equipment	Operating	20.1	29.8	+9.7
Business	Profit	(20.1)	(29.8)	
Haalibaana	Revenue	25.2	29.4	+17%
Healthcare Business	Operating	-2.1	-2.3	-0.2
Du 3iiic33	Profit	(-2.1)	(-2.3)	
Industrial	Revenue	29.8	33.7	+13%
Metrology and	Operating	1.5	2.7	+1.2
Others	Profit	(1.5)	(3.5)	
Corporate	Revenue	_	-	-
Profit/Loss non- attributable to any	Operating	-11.9	-12.8	-0.9
reportable segments	Profit	(-11.9)	(-12.8)	
	Revenue	328.4	335.7	+2%
Consolidated	Operating	23.0	30.6	+7.6
	Profit	(23.0)	(31.8)	

Note: Due to change of revenue recognition under IFRS15, part of sales promotion expenses are deducted from Revenue of FY2019/3. $_{5}$ Figures of Operating Profit in parentheses shows those excluding the restructuring cost.

2nd Quarter of the Year ending March 31,2019: Financial Highlights



Billions of yen	FY2018/3 Q2 (A)	FY2019/3 Q2 (B)	Change (B)-(A)
Revenue	158.1	168.8	+10.7
Operating Profit % vs Revenue	10.6 6.7%	11.6 6.9%	+1.0
Profit before Income taxes % vs Revenue	8.3 5.2%	11.9 7.0%	+3.6
Profit attributable to Owners of the Parent % vs Revenue	5.1 3.2%	6.5 3.9%	+1.4
Exchange Rate: US \$ EURO	¥111 ¥130	¥111 ¥130	Impact on Revenue -0.8 Impact on Op. Profit -0.9

Sales of FPD lithography systems for large-sized panels more than doubled resulting in hike of profit.

First Half of the Year ending March 31, 2019: Imaging Products Business



Billions of yen	FY2018/3 1H (A)	Previous forecast (B) (Aug.7)	FY2019/3 1H (C)	Change (C)-(A)	Change (C)-(B)
Revenue	175.2	150.0	150.9	-24.3	+0.9
Operating Profit	15.4	15.0	13.2	-2.2	-1.8
% vs Revenue	8.8%	10.0%	8.7%		
Digital Camera- Interchangeable Lens type (units sold: 1,000)	1,310	_	1,070	-240	_
Interchangeable Lens (units sold: 1,000)	2,020	_	1,650	-370	-
Compact DSC (units sold: 1,000)	1,390	_	850	-540	_

- YoY: Sales and profit declined. The shift to high-valued added products compensated for the hit to profits from market shrinkage. However, profit was still pushed down by the high initial cost for ML cameras.
- **Actual vs. forecast:** With the announcement of ML camera launch, more customers than expected refrained from purchasing existing products. Units sold, revenue (excluding forex impact) and 1H profit missed plan.

First Half of the Year ending March 31, 2019: Precision Equipment Business



Billions of yen	FY2018/3 1H (A)	Previous forecast (B) (Aug.7)	FY2019/3 1H (C)	Change (C)-(A)	Change (C)-(B)
Revenue	98.0	124.0	121.6	+23.6	-2.4
Operating Profit	20.1	30.0	29.8	+9.7	-0.2
% vs. Revenue	20.5%	24.2%	24.5%		
FPD Lithography Systems (units)	34	_	36	+2	_
Semiconductor Lithography systems New/Refurbished (units)	7/4	_	8/9	+1/+5	_

- YoY: Sales and profit grew, driven in large part by increased volumes of FPD lithography systems for large-sized panels including high-priced G10.5.
- **Actual vs. forecast:** Profit in line because COGS improvements and other operational efforts picked up the slack as some sales of semiconductor lithography systems were pushed into 2H.

First Half of the Year ending March 31, 2019: Healthcare Business



Billions of yen	FY2018/3 1H (A)	Previous forecast (B) (Aug.7)	FY2019/3 1H (C)	Change (C)-(A)	Change (C)-(B)
Revenue	25.2	26.0	29.4	+4.2	+3.4
Operating Profit	-2.1	-5.0	-2.3	-0.2	+2.7
% vs. Revenue	-8.3%	-19.2%	-7.8%		

- YoY: Significant increase of revenue due to the biological microscopes sales growth mainly in overseas markets. Operating loss stayed flat due to strengthening of strategic investments in retinal diagnosis systems and regenerative medicine fields.
- Actual vs. forecast: Operating loss was halved as gross profit improved, driven by revenue growth, and some expenditures were deferred to 2H.

First Half of the Year ending March 31, 2019: Industrial Metrology Business and Others



Billions of yen	FY2018/3 1H (A)	Previous forecast (B) (Aug.7)	FY2019/3 1H (C)	Change (C)-(A)	Change (C)-(B)
Revenue	29.8	32.0	33.7	+3.9	+1.7
Operating Profit	1.5	2.0	2.7	+1.2	+0.7
% vs. Revenue	5.0%	6.3%	8.0%		

- **YoY:** Revenue/profit improved in all businesses. Industrial Metrology started to demonstrate the restructuring benefit, posting the 1H operating profit (excluding temporary expense) for the first time after the Lehman shock.
- **Actual vs. forecast:** Beat plan. Although Industrial Metrology booked an additional ¥600 million restructuring cost, some sales were front loaded from 2H and other businesses improved their profitability.



1. Financial results for the second quarter of the Year ending March 31, 2019

2. Forecast for the Year ending March 31, 2019

3. Capital allocation of post-restructuring

Forecast for the Year ending March 31, 2019



Revenue

- Overall forecast remains unchanged.
 - The previous forecast stays unchanged.

Operating Profit

- Overall forecast remains unchanged.
 - Imaging Products Business forecast is lowered by ¥2 billion based on the 1H result. However, the forecasts of Healthcare Business and Corporate, which is not attributable to any reportable segments, are upgraded by ¥1 billion each.

Profit attributable to owners of the parent

- Overall forecast remains unchanged.
 - ROE improves to 9% range for the first time in five years. Solidify a level of profitability above our capital cost, then pursue higher profitability over the midterm.

Annual Dividend

- ¥60 (¥30 interim, ¥30 year-end)
 - Up ¥24 from ¥36 of the previous year,
 Up ¥6 from ¥54 of the previous forecast.

Forecast for the Year ending March 31, 2019: Financial Highlights



Billions of yen	FY2018/3 Actual (A)	Previous Forecast (Aug.7) (B)	New Forecast (Nov.8) (C)	Change (C)-(A)	Change (C)-(B)
Revenue	717.0	740.0	740.0	+23.0	±0.0
Operating Profit % vs Revenue	56.2 7.8%	74.0 _{10.0%}	74.0 _{10.0%}	+17.8	±0.0
Profit before income taxes % vs Revenue	56.2 7.8%	76.0 10.3%	76.0 10.3%	+19.8	±0.0
Profit attributable to owners of the parent % vs Revenue	34.7 4.8%	53.0 7.2%	53.0 7.2%	+18.3	±0.0
FCF	90.2	60.0	60.0	-30.2	±0.0
Exchange Rate :				Impact or	Revenue
US\$ EURO	¥111 ¥130	¥106 ¥130	¥108 ¥130	approx9.3 Impact on approx2.2	approx.+2.5 Op. Profit approx.+0.1

FCF forecast remains unchanged as well as Revenue and Profits.

Forecast for the Year ending March 31, 2019: Financial Highlights by Segment




Billions of yen		FY2018/3 Actual(A)	Previous Forecast (Aug.7) (B)	New Forecast (Nov.8) (C)	Change (C)-(A)	Change (C)-(B)
Imaging	Revenue	360.7	320.0	320.0	-11.3%	±0%
Products	Operating	30.2	33.0	31.0	+0.8	-2.0
Business	Profit	(36.0)	(34.0)	(32.0)		
Precision	Revenue	226.3	282.0	282.0	+24.6%	±0%
Equipment	Operating	53.3	68.0	68.0	+14.7	±0.0
Business	Profit	(53.3)	(68.0)	(68.0)		
	Revenue	56.8	63.0	63.0	+10.9%	±0%
Healthcare Business	Operating	-3.2	-4.0	-3.0	+0.2	+1.0
Dusiness	Profit	(-3.2)	(-4.0)	(-3.0)		
Industrial	Revenue	73.2	75.0	75.0	+2.5%	±0%
Metrology and	Operating	5.0	6.0	6.0	+1.0	±0.0
Others	Profit	(7.8)	(6.0)	(7.0)		
Corporate	Revenue	_	_	-	_	_
Profit/Loss non- attributable to any	Operating	-29.1	-29.0	-28.0	+1.1	+1.0
reportable segments	Profit	(-29.1)	(-29.0)	(-28.0)		
	Revenue	717.0	740.0	740.0	+3.2%	+0%
Consolidated	Operating	56.2	74.0	74.0	+17.8	±0.0
	Profit	(64.9)	(75.0)	(76.0)		

Note: Due to change of revenue recognition under IFRS15, part of sales promotion expenses are deducted from Revenue of FY2019/3. FY19/3 Revenue forecast is an amount after deducting approximately ¥7 billion.

Figures of Operating Profit in parentheses shows those excluding the restructuring cost.

Forecast for the Year ending March 31, 2019: **Imaging Products Business**





Market Scale	11,410	10,000	9,800					
Nikon	2,620	2,300	2,250					
Interchangeable Lenses (units: 1,000)								
Market Scale	19,060	16,500	16,300					
Nikon	4,010	3,400	3,350					
Compact DSC (units: 1,000)								
Market Scale	11,960	8,000	8,000					

1,700

2,510

Nikon

Revenue: forecast unchanged, down ¥40.7 billion YoY

- ASP is buoyed by new products introduction including full-frame ML cameras.
- Sales volume forecast is revised based on the 1H result, but the impact is offset by forex contribution to sales hike.

Operating Profit: forecast down by ¥2 billion, but ¥800 million up YoY


- FY18/3 and FY19/3 OP before restructuring costs ¥36B and ¥32B, respectively.
- Yearly restructuring cost amounts to ¥1 billion, among which ¥600 million is deferred to 2H.
- Revised down ¥2 billion vs. previous forecast to reflect 1H plan miss.

Note: Due to change of revenue recognition under IFRS15, part of sales promotion expenses are deducted from Revenue of FY2019/3. 15 FY19/3 Revenue forecast is an amount after deducting approximately ¥7 billion.

1,700

Forecast for the Year ending March 31, 2019: Precision Equipment Business





Revenue: forecast unchanged, up ¥55.7 billion YoY


- FPD: No change in the forecast, which calls for sales growth in largesized panel systems to exceed the sales drop of mid-to-small sized panel systems.
 - G10.5 significantly grows to 18 units from 3 units (last FY).
- Semiconductor: Sales volume increases due to the steady customers' CAPEX.

Operating Profit: forecast unchanged, up ¥14.7 billion YoY

- FPD: Substantial improvement in revenue and profit
- Semiconductor: Achievement of two consecutive profitable years to confirm that a profitable business structure has taken hold.

Forecast for the Year ending March 31, 2019: Healthcare Business





Revenue: forecast unchanged, up ¥6.2 billion YoY


- Bioscience: Expect to increase revenue mainly in overseas such as North America and China.
- Ophthalmologic diagnosis: Forecasting revenue growth as the retinal imaging diagnostic system market remains robust and new product launches.

Operating Profit: forecast up by ¥1 billion

 More strategic investments than last FY have been executed to expand business and grow profit. But the loss stays almost flat YoY, supported by sales hike.

Forecast for the Year ending March 31, 2019: Industrial Metrology Business and Others





Revenue: forecast unchanged, up ¥1.8 billion YoY

 In Industrial Metrology, revenue decline resulting from the CMM business disposition is covered by sales expansion of image measuring systems and X-ray inspection systems, etc.

Operating Profit: forecast unchanged, up ¥1 billion YoY

- FY18/3 and FY19/3 OP before the restructuring cost ¥7.8B and ¥7.0B, respectively.
- Additional restructuring cost accompanied by products discontinuation is absorbed by revenue/profit improvement.
- Restructuring cost is ¥1 billion for the full year.



1. Financial results for the second quarter of the Year ending March 31, 2019

2. Forecast for the Year ending March 31, 2019

3. Capital allocation of post-restructuring

Capital allocation of post-restructuring



Assessment of Current Situation

- Restructuring efforts transformed the company operations to pursue profit with appropriate fixed cost, and became capable of stably generating profit consistently in the midterm timeframe.
- However, we are still working on building a foundation for sustainable growth in corporate value and **creating/strengthening growth engines** is an urgent priority.
- We can maintain the higher level of dividend returns achieved through restructuring, even as we absorb the need to invest in growth and volatility in business performance and the markets.

Capital Allocation Principle


• While realizing appropriate returns to our shareholders, we shall **prioritize strategic investments for growth** in order to generate new operating cash flows that are essential to improve corporate value.

Return Policy

- Return policy for the next midterm: **Keep ¥60 or more dividend**
 - If ¥60 falls short of our current policy to pay "a dividend payout ratio of 40% or more," we will consider additional returns to our shareholders as appropriate.
 - If the environment surrounding us drastically changes, this policy (¥60 or more dividend) may be revised depending on the investment capacity for growth and the capital structure.
- Aiming to enhance and stabilize returns to our shareholders and improve capital efficiency in a long-term perspective.

Dividend history and forecast







NIKON CORPORATION



Reference Data

Forecast for the Year ending March 31, 2019: Financial Highlights (Half Year/Full Year)



	FY17/3		FY18/3		FY19/3	Forecast	(Nov.8)
Billions of yen	2017/3	1H	2H	2018/3	1H	2H	2019/3
Revenue	749.2	328.4	388.6	717.0	335.7	404.3	740.0
Operating Profit	0.7	23.0	33.2	56.2	30.6	43.4	74.0
% vs Revenue	0.1%	7.0%	8.5%	7.8%	9.1%	10.7%	10.0%
Profit before income taxes	3.0	21.4	34.8	56.2	33.8	42.2	76.0
% vs Revenue	0.4%	6.5%	9.0%	7.8%	10.1%	10.4%	10.3%
Profit attributable to owners of the parent	3.9	13.9	20.8	34.7	22.8	30.2	53.0
% vs Revenue	0.5%	4.2%	5.4%	4.8%	6.8%	7.5%	7.2%
FCF	56.6		90.2			60.0	
Exchange Rate: US \$ EURO	¥108 ¥119	¥111 ¥126	¥111 ¥133	¥111 ¥130	¥110 ¥130	¥105 ¥130	¥108 ¥130

Note: Due to change of revenue recognition under IFRS15, part of sales promotion expenses are deducted from Revenue of FY2019/3. FY19/3 Revenue forecast is an amount after deducting approximately ¥7 billion.

Forecast for the Year ending March 31, 2019: Financial Highlights by Segments (Half Year/Full Year)



		FY17/3		FY18/3		FY19/3	Forecast	(Nov.8)
Billions of yen	_	2017/3	1H	2H	2018/3	1H	2H	2019/3
Imaging	Revenue	383.0	175.2	185.5	360.7	150.9	169.1	320.0
Products	Operating	17.1	15.4	14.8	30.2	13.2	17.8	31.0
Business	Profit	(28.1)	(15.4)	(20.6)	(36.0)	(13.6)	(18.4)	(32.0)
Precision	Revenue	248.0	98.0	128.3	226.3	121.6	160.4	282.0
Equipment	Operating	13.4	20.1	33.2	53.3	29.8	38.2	68.0
Business	Profit	(48.1)	(20.1)	(33.2)	(53.3)	(29.8)	(38.2)	(68.0)
Haalkhaaya	Revenue	55.7	25.2	31.6	56.8	29.4	33.6	63.0
Healthcare Business	Operating	-0.6	-2.1	-1.1	-3.2	-2.3	-0.7	-3.0
Dusiness	Profit	(-0.1)	(-2.1)	(-1.1)	(-3.2)	(-2.3)	(-0.7)	(-3.0)
Industrial	Revenue	62.4	29.8	43.4	73.2	33.7	41.3	75.0
Metrology and	Operating	3.7	1.5	3.5	5.0	2.7	3.3	6.0
Others	Profit	(5.5)	(1.5)	(6.3)	(7.8)	(3.5)	(3.5)	(7.0)
Corporate	Revenue	_	_	_	_	_	_	_
Profit/Loss non- attributable to any	Operating	-32.8	-11.9	-17.2	-29.1	-12.8	-15.2	-28.0
reportable segments	Profit	(-27.5)	(-11.9)	(-17.2)	(-29.1)	(-12.8)	(-15.2)	(-28.0)
	Revenue	749.2	328.4	388.6	717.0	335.7	404.3	740.0
Consolidated	Operating	0.7	23.0	33.2	56.2	30.6	43.4	74.0
	Profit	(54.1)	(23.0)	(41.9)	(64.9)	(31.8)	(44.2)	(76.0)
Note: Due to change of					expenses are	deducted from	Revenue of FY	2019/3.


25 FY19/3 Revenue forecast is an amount after deducting approximately ¥7 billion.

2nd Quarter of the Year ending March 31,2019: Financial Position Breakdown



ASSETS

LIABILITIES/EQUITY



Note: A Breakdown of interest-bearing debt as of September 30, 2018 is ¥29.9B in bonds and ¥99.8B in other borrowings. Equity ratio is ratio of equity attributable to owners of the parent to total assets.


Cash and Cash Equivalents excludes time deposits with maturities of three months or more.


Forecast for the Year ending March 31, 2019: Capital Expenditures, Depreciation and Inventory



CAPITAL EXPENDITURES, DEPRECIATION

INVENTORY BREAKDOWN







Note: Figures after FY2016/3 is presented in International Financial Ruling Standards (IFRS) while FY2015/3 is in Japan GAAP. Depreciation expenses comprise in-process development costs as from FY2017/3. Inventory breakdown before FY2016/3 is reclassified under the current business segmentation.



R&D EXPENDITURES

R&D EXPENDITURES BREAKDOWN






Note: R&D expenditures after FY2018/3 includes capitalization of some development expenditure. Breakdown is shown for two years in view of the segmentation change since previous fiscal year.




SALES IN UNITS BY PRODUCT CATEGORY






FPD LITHOGRAPHY SYSTEMS SALES BY GENERATION


SEMICONDUCTOR LITHOGRAPHY SYSTEMS SALES BY TECHNOLOGY (INCL. REFURBISHED)








FPD LITHOGRAPHY SYSTEMS SALES IN UNITS BY GENERATION





SEMICONDUCTOR LITHOGRAPHY SYSTEMS SALES IN UNITS BY TECHNOLOGY (INCL. REFURBISHED)



Forecast for the Year ending March 31, 2019: Foreign Exchange Rate Impact



	Exchange Rate	Financial Impact from fluctuation by 1 yen	
	FY19/3 2H Assumption	Revenue 2H	Operating Profit 2H
US\$	¥ 105	Approx. ¥1.5 billion	Approx. ¥0.1 billion
EURO	¥130	Approx. ¥0.4 billion	Approx. ¥0.2 billion



NIKON CORPORATION